Cardiome Appoints New Director and Announces Current Board Members.Business Editors VANCOUVER, British Columbia--(BUSINESS WIRE)--March 15, 2002 Cardiome Pharma Corp. (the "Company") announced today the appointment of Dr. Ralph Snyderman to the Board of Directors. With Dr. Snyderman's appointment, the Company will have nine Board members including Dr. Mark Rogers who has now assumed the position of Chairman of the Board. "Dr. Snyderman brings with him valuable experience having served as a senior officer with Genentech," said Bob Rieder, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cardiome. "This experience, in addition to the prominent role he serves at Duke University Health System, a fully integrated academic health system in the U.S., will be important to Cardiome as we continue to build our organization in the coming years." In addition to Drs. Rogers and Snyderman, the current board members include Michael Walker, Ph.D. (Founder and former Chairman), Robert Rieder, M.B.A., President and CEO, Alan Ezrin, Ph.D., Chief Scientific Officer, Kim Sun Oh, Myron Weisfeld, M.D., Elizabeth Rogers, M.D., and Fred Mermelstein, Ph.D. Biographies of all Board Members are posted on the Company's website at www.cardiome.com. About Ralph Snyderman, M.D. Dr. Snyderman currently serves as President and CEO of the Duke University Health System based in North Carolina. He plays a prominent role in the leadership of such important national organizations as the Association of American Physicians, the Institute of Medicine and the Association of American Medical Colleges Association of American Medical Colleges, n.pr a nonprofit organization founded in 1876 to reform medical education and represent medical schools, major teaching hospitals, scientific and academic faculty, medical students, and residents. ("AAMC") that represents all U.S. medical schools and teaching hospitals. He currently serves as Chair of the AAMC. In 1987, Dr. Snyderman joined Genentech, the pioneering biomedical technology firm, as Vice President for medical research and development and member of their senior leadership team. A year later, he was promoted to senior vice president. While at Genentech, he led the development and licensing of several novel therapeutics and supervised approximately 300 staff members working in pharmacology, clinical research and regulatory affairs. A graduate of Washington College in Chestertown, Md. (1961), Snyderman received his M.D., magna cum laude, in 1965 from the Downstate Medical Center of the State University of New York (body) State University of New York - (SUNY) The public university system of New York State, USA, with campuses throughout the state. . He served his internship and residency in medicine at Duke and later worked as a Public Health Officer doing research in immunology at the NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. (1967-72). Dr. Snyderman received his first faculty appointment at Duke in 1972 where he rose rapidly through Duke's academic ranks, becoming Chief of the Division of Rheumatology and Immunobiology. By 1984, Snyderman was also the Frederic M. Hanes Professor of Medicine and Immunology. Following his career at Genentech, he returned to Duke as the James B. Duke Professor At Duke University, the title of James B. Duke Professor is given to a small number of the faculty with extraordinary records of achievement. At some universities, titles like "Distinguished Professor," "University Professor," or "Regents Professor" are counterparts of this title of Medicine in 1989 and Executive Dean since 1999. His bibliography approaches 350 manuscripts as well as numerous books. About Cardiome Pharma Corp Cardiome Pharma Corp. is a product-focused cardiac drug discovery and development company. The Company's mission is to prevent and treat heart disease. The Company has four drug programs focused on arrhythmias and congestive heart failure congestive heart failure, inability of the heart to expel sufficient blood to keep pace with the metabolic demands of the body. In the healthy individual the heart can tolerate large increases of workload for a considerable length of time. . The congestive heart failure program is ready for Phase II development. RSD RSD Reflex sympathetic dystrophy, see there 1235, intended for the acute treatment of atrial fibrillation, is currently being tested by the Company in a Phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II . RSD1122, intended for chronic treatment of atrial and ventricular arrhythmia, is in pre-clinical development with AstraZeneca, one of the world's largest pharmaceutical companies. The Company's Kv1.5 antiarrhythmic antiarrhythmic /an·ti·ar·rhyth·mic/ (-ah-rith´mik) 1. preventing or alleviating cardiac arrhythmias. 2. an agent that so acts. an·ti·ar·rhyth·mic adj. program, focused on the chronic treatment of atrial fibrillation, is also in the pre-clinical phase at Cardiome. The Company's facilities are on the grounds of the University of British Columbia Locations Vancouver The Vancouver campus is located at Point Grey, a twenty-minute drive from downtown Vancouver. It is near several beaches and has views of the North Shore mountains. The 7. in Vancouver. Cardiome is traded on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. (COM) and the NASD NASD See: National Association of Securities Dealers NASD See National Association of Securities Dealers (NASD). OTCBB OTCBB See OTC Bulletin Board (OTCBB). market (COMRF.OB). Forward-Looking Statement Disclaimer Statements contained in this news release relating to future results, events and expectations are forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such statements. Such factors include, among others, those described in the Company's annual report on Form 20-F on file with the U.S. Securities and Exchange Commission. The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. ON BEHALF OF THE BOARD Robert Rieder President & Chief Executive Officer |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion